Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
Cathie Wood believes in the potential of gene editing. She stated last December that the "biggest upside surprises are going to come from the genomic space."It's not surprising that Wood'sARK Genomic Revolution ETF(NYSEMKT:ARKGARK Innovation ETFNYSEMKT:ARKKgene-editing stocksImage source: Getty Images.Selling before the news?The ARK Innovation ETF recently sold some of its shares ofEditas MedicineNASDAQ:EDITThere's an old investing adage to "buy the rumor and sell the news." In this case, perhaps Wood is doing a little selling before the news. Editas is scheduled to present data on Sept. 9 from its phase / clinical study evaluating CRISPR gene-editing therapy EDIT-0 in treating rare genetic eye disorder Leber congenital amaurosis 0.As would be expected, Editas hasn't given any clear hints about how good its data might be. On the company's second-quarter conference call, Chief Medical Officer Lisa Michaels said that Editas was "very happy with how this trial [of EDIT-0] has progressed
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $86.00 price target on the stock.MarketBeat
- CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Wells Fargo & Company from $70.00 to $65.00. They now have an "equal weight" rating on the stock.MarketBeat
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Barclays PLC from $80.00 to $67.00. They now have an "equal weight" rating on the stock.MarketBeat
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 4/17/24 - Form 4
- CRSP's page on the SEC website